The global pharmaceutical and biotechnology industry is undergoing a major transformation, driven by the rapid growth of regenerative medicine, biologics, and advanced therapeutic technologies. As a result, the market for pharma companies for sale is expanding, offering unique opportunities for investors, healthcare groups, and biotechnology entrepreneurs.
Today, pharmaceutical businesses available for acquisition range from specialized oncology companies and dermatology brands to contract manufacturing organizations (CMOs) and distribution-focused enterprises. Many of these companies operate with established product portfolios, regulatory approvals, and existing market access, making them attractive investment targets. For example, some companies listed for sale include oncology-focused firms with active marketed products and expansion potential across Europe, as well as profitable dermatology businesses with strong brand recognition and consistent revenue growth .
At the same time, the industry is shifting from traditional pharmaceutical models toward biotechnology-driven solutions, including cell-based therapies, gene therapies, and personalized medicine. This transformation is significantly increasing the strategic value of companies involved in biopharmaceutical production, clinical research, and regenerative medicine platforms.
In a biotechnology laboratory in Barcelona, Spain, advanced research is focused on stem cell therapy and its clinical applications. These include the use of mesenchymal stem cells for immune modulation, tissue regeneration, and support of recovery in complex diseases. This evolution reflects a broader industry trend where the value of pharmaceutical companies is no longer limited to product sales but increasingly linked to their role in developing innovative therapeutic solutions.
The pharmaceutical sector is expected to continue rapid expansion, with global markets driven by breakthroughs in personalized medicine, biologics, and advanced therapies . This creates a strong environment for mergers, acquisitions, and strategic investments, especially in companies aligned with next-generation medical technologies.
Below is a selection of pharmaceutical companies and biotech businesses for sale, including opportunities across Europe, Latin America, and global markets.
1M+ revenue German oncology company for sale
Privately owned pharmaceutical company, specialized in the field of oncology (generics, parenteral), strong in the private sector market with clinical phase IV studies. 5 products actively marketed, 4 products to be launched. The business model is marketing and selling to oncologist in Germany.
Production is outsourced to well-known and reliable CMOs. Supply chain is secured. Licensor agreed to extend territory to pan-Europe, if requested. Revenue 1M+, profitable, EBITDA 15%, 5 employees.
More information
1,3 M Euro EBITDA Dermatology company in Italy for sale
Privately owned Italian pharmaceutical company founded in 2000, focused in dermatology field. Strong brands are amongst the most recommended by dermatologists in Italy. Product range of Cosmeceuticals, Medical Devices and Food Supplements for treatment of several dermatological pathologies. The Company has a team of 8 employees: a highly educated professional staff with substantial experience and are promoted by highly skilled 27 reps sales force (exclusive agents). Financials 2016 – 5.35M Euro revenue, 1.3M Euro EBITDA; 2017B 6.0M Euro revenue, 1.4M Euro EBITDA; 24% EBITDA margin, 15% annual revenue growth, No debts. Shareholders are willing to sell 100% of the shares
More information
3,5 M Euro revenue Italian CMO for sale
Oral solids and liquids, pharmaceutical and Medical devices, 35 employees, 3.5 M Euro revenue, EBITDA <0
More information
200 K Euro revenue brand divestment in Germany
MA and brand in Germany in Hormone replacement therapy (HRT) for the relief of complaints during or after menopause as well as osteoporosis prevention. For sale is a longterm established and marketed product, German MA granted no limits, no expiration + Trademark. Without promotion activities stable annual revenues of 200.000 Euro. Product is in the reimbursement list. Possibility to co-operate with existing CMO or own production to be discussed. Stock is available for a smooth business transaction.
More information
1M Euro revenue Hospital businesses in Spain for sale
The company registers and distributes high quality pharmaceutical products (contrast agents for X-ray, CT and MRI) in an exclusive agreement; it holds own MAHs and Brands for the Spanish market and distributes these products to the hospitals. The company is about to launch a new generation of radiological products in the Spanish market, as well as registering and commercializing new oncology diagnostic products 10 people, 7 of which are sales force covering different regions. Annual revenue app. 1 M Euro, gross margin approximately 55%.
More information
13M+ USD growing profitable Pharmaceutical Company for sale in Brazil
Privately owned pharmaceutical company based in Brazil that produces and commercializes pharmaceutical products with its own brands. ANVISA approved plant, where it has registered 31 products. Sales: Liquids 62%, Solids 25%, Semisolids 13%; Distribution of Sales: OTC – 37%, Phytopharmaceuticals – 29%, Generic drugs – 17%, 42.500 m2 of industrial space recently acquired and approved by ANVISA for industrial use. Regional Tax Incentives: reduction of 75% of Income Tax for 10 years, between other fiscal incentives for industrials. Revenues 2016: 43.5 M Reals (13M+ USD), EBITDA 2016: 4.7 M Reals (1.4 M USD), 330 Employees: Sales CAGR 2006-2016 12%
More information
25M+ Euro revenue profitable European company for sale
Fast growing pharmaceutical sales & marketing group with ca. 20 employees, product portfolio of 150 high quality Rx and OTC products (mostly EU CTD dossiers produced in EU GMP plants), therapeutic categories – central nervous system, cardiovasculars, oncology, gastroenterology, respiratory, pain management, osteoporosis, allergology, infectiology, around 600 MAs already granted globally, additional 50 MAs pending under ongoing regulatory procedures, main operations in Germany, also in EU markets: UK, Denmark, Poland, Netherlands, Portugal, Italy, Spain, other and international sales in 33 countries. Cooperating with selected top-notch manufacturers in Europe and Asia. EU GMP and Wholesaler License, EU Import License, no real estate, no production plant, no bank loans, no pension liabilities. 25M Euro revenue; 1.8M Euro EBITDA for 2017 with a carefully selected product portfolio.
More information
8M Euro revenue profitable pharma company for Sale in West Europe
The company manages the marketing, selling and distribution of pharmaceutical/medical supplies and devices in the several markets of North Western Europe. The 8 million euro business growing and profitable business. Pharmaceuticals/devices currently represented include injectables, infusions, tablets and devices addressing the areas of pain management, womens reproductive health, fungal infection and thyroid conditions. Besides managing their own products, the company also represents international organisations that do have not have a local marketing, sales and distribution representative. Company do not have own production plant.
More information
EU GMP running injectable manufacturing plant in Spain for sale
Profitable and growing CDMO (contract development & manufacturing organization) is available for sale. 15 employees, own land (5.000 sq.m), building (2.000 sq.m.), equipment, no debts. Manufacturing in glass container, PP container, PP bags, irrigation solutions. Products New 3 ophthalmology lines (mono-dose and multi-dose) EU GMP approval expected within 2017.
More information
18+ M Euro profitable growing ANVISA distributor in Brazil for sale
Based in So Paulo, Specialised in the field of otorhinolaryngology and orthopaedic, represents two of the largest global suppliers with exclusivity in the Brazilian market. Clients of the company are mainly private (95%) with only 5% of government buyers. Its strategic position in the Brazilian market is coupled by a solid image in the medical profession and clients with unblemished reputation and tradition for over 30 years. Growing annual revenue: 2016 – 14.7 M Euro, EBITDA (26%) 3.8 M Euro, 90 employees, no debts, net cash 1.5 M Euro. Motivation for sale: evaluating other business scenarios.
More information
3.7+ USD profitable growing PICS GMP plant in Indonesia for sale
Established in 1984, PICS GMP running (last approval in 2016) manufacturing plant in Jakarta, Indonesia 5,167 sq.m. of land, 3,184 sq.m. of building and new machines installed in 2014 and 2015.
3 business divisions: Generics, Specialty and Herbal. Total of 164 SKUs.
Market leader for Anti-inflammatory product covers 60+% of anti inflammatory products in Indonesia.
Products are distributed to cities in 31 provinces in Indonesia through 23 distributors, such as Kimia Farma, Tempo, and Mensa Bina Sukses. Parcipating in government tenders. Production capacity 1 M tablets / day will be increased with the new machines. 50% is used capacity at the moment. 135 employees, Assets 11.4 M USD, Annual revenue 3.7 M USD, EBITDA 22%,
More information
Seeking to sell pharmaceutical company or brand divestment ?
On behalf of our clients we are looking to acquire pharmaceutical business in USA, EU, MENA, Asia, LATAM. We are interested in brand divestments, pharmaceutical business with/without factories for sale. Please e-mail [email protected]
Pharma Companies for Sale, Biotechnology Investments, and the Future of Regenerative Medicine
The market for pharmaceutical companies for sale is becoming increasingly dynamic as the industry shifts toward innovation-driven models. Investors are no longer focused solely on traditional drug portfolios but are активно seeking opportunities in biotechnology, cell therapy, and advanced medical platforms.
In particular, companies involved in stem cell therapy, regenerative medicine, and biopharmaceutical development are gaining significant attention due to their long-term growth potential and clinical relevance. Research conducted in a biotechnology laboratory in Barcelona, Spain highlights the growing importance of mesenchymal stem cells and personalized treatment approaches in modern medicine.
The convergence of pharmaceutical manufacturing, clinical research, and biotechnological innovation is redefining the industry landscape. As demand for advanced therapies continues to rise, acquiring or investing in pharmaceutical and biotech companies represents a strategic pathway for entering the future of healthcare.
The information on this page is intended for scientific, educational, and general informational purposes. Clinical approaches, availability, and regulatory status may vary by country, institution, and medical indication. For individual medical decisions, readers should consult qualified healthcare professionals and accredited medical centers.
This article has been prepared by the NBScience editorial team within the scope of clinical research, biotechnology, and international medical information.
